The Guardian
Email YouTube Facebook Instagram Twitter WhatsApp

WHO prequalifies first biosimilar medicine to increase access to cancer treatment

Related


The World Health Organization (WHO) has prequalified its first biosimilar medicine, trastuzumab in a move to enable women with breast cancer all over the world get affordable and accessible treatment. According to body, about 2.1 million women contacted breast cancer in 2018, as 630 000 of them died from the disease, due to late diagnosis and lack of access to affordable treatment.

Also, a recent study of breast cancer in sub-Saharan Africa found that, of 1325 women surveyed in three countries, cancer treatment had not been initiated within one year of diagnosis for 227 (17%) women and for 185 (14%) women with stage I-III disease. Also, self-reported treatment barriers confirmed treatment costs as a major contributor to not receiving treatment.Trastuzumab is a monoclonal antibody, which was included in the WHO Essential Medicines List in 2015 as an essential treatment for about 20 percent of breast cancers.

It has, however, shown high efficacy in curing early stage breast cancer and in some cases more advanced forms of the disease, according to WHO.The Director-General, WHO, Dr. Tedros Adhanom Ghebreyesus, said the body’s prequalification of biosimilar trastuzumab is good news for women everywhere.He said: “Women in many cultures suffer from gender disparity when it comes to accessing health services. In poor countries, there is the added burden of a lack of access to treatment for many, and the high cost of medicines. Effective, affordable breast cancer treatment should be a right for all women, not the privilege of a few.”

Ghebreyesus stated that the global average cost of trastuzumab from originator companies at $20 000, made it difficult for many women and healthcare systems in most countries to reach. He said the body moved to create the biosimilar version of trastuzumab, which he said is 65 percent cheaper than the originator, adding: “With this WHO listing, and more products expected in the prequalification pipeline, prices should decrease even further.”

It was however disclosed that the medicine, which was supplied by Samsung Bioepis NL B.V. (Netherlands), was assessed by WHO and found comparable to the originator product in terms of efficacy, safety and quality, which means it is eligible for procurement by United Nations agencies and for national tenders, according to the international body.

However, Biotherapeutic medicines, which are produced from biological sources such as cells rather than synthesised chemicals, are important treatments for some cancers and other non-communicable diseases. Like generic medicines, biosimilars can be much less expensive versions of innovator biotherapeutics while keeping the same effectiveness.

Meanwhile few biosimilars of trastuzumab have come to market in the last five years, but none had been prequalified by WHO before today. WHO prequalification gives countries the assurance that they are purchasing quality health products.However, WHO’s International Agency for Research on Cancer estimates that by 2040 the number of diagnosed breast cancers will reach 3.1 million, with the greatest increase in low- and middle-income countries.

“We need to act now and try to avoid more preventable deaths,” says Dr Mariângela Simão, WHO Assistant Director General for Medicines and Health Products. “The availability of biosimilars has decreased prices, making even innovative treatments more affordable and hopefully available to more people.”


Receive News Alerts on Whatsapp: +2348136370421

No comments yet